OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Levy on Potential Methods to Optimize Molecular Testing in Lung Cancer

February 7th 2022

Benjamin Philip Levy, MD, discusses potential methods to optimize molecular testing in lung cancer.

Dr. Basu Roy on Addressing Barriers to Biomarker Testing in Lung Cancer

February 5th 2022

Upal Basu Roy, PhD, MPH, discusses addressing barriers to biomarker testing in lung cancer.

Dr. Hales on Investigational Treatment Strategies to Build Upon the PACIFIC Trial Results in Stage III NSCLC

February 5th 2022

Russell Kenneth Hales, MD, discusses investigational treatment strategies that have the potential to build upon the positive results of the phase 3 PACIFIC trial in stage III non–small cell lung cancer.

Dr. Sands on the Importance of NGS Testing in Lung Cancer

February 4th 2022

Jacob Sands, MD, physician, discusses the importance of next-generation sequencing testing in lung cancer.

Dr. Korde on Updated Findings From the Cassiopeia Trial in Multiple Myeloma

February 4th 2022

Neha S. Korde, MD, hematologist, Memorial Sloan Kettering Cancer Center, discusses key updates to the phase 3 Cassiopeia study (NCT02541383) in multiple myeloma.

Dr. Azzi on the Utilization of the Signatera ctDNA Assay in the CIRCULATE-US Trial in CRC

February 4th 2022

Georges Azzi, MD, co-director, Department of Hematology/Oncology, Prostate Cancer, Holy Cross Health, discusses the utilization of the Signatera circulating tumor DNA assay in the ongoing phase 2/3 CIRCULATE-US trial in colorectal cancer.

Dr. Ross Discusses Advances in Recognizing, Screening, and Treating CRC

February 3rd 2022

Howard M. Ross, MD, discusses advances in recognizing, screening, and treating patients with colorectal cancer.

Dr. Phillips on the Current Role of Ibrutinib in MCL

February 3rd 2022

Tycel Jovelle Phillips, MD, discusses the current role of ibrutinib in mantle cell lymphoma.

Dr. Ramalingam on the Results of an Exploratory Analysis of the CheckMate 227 Trial in NSCLC

February 3rd 2022

Suresh S. Ramalingam, MD, FACP, FASCO, discusses the results of an exploratory analysis of the ongoing phase 3 CheckMate 227 trial in advanced non–small cell lung cancer.

Dr. Spring on Next Steps of the AMEERA-1 Trial in ER+/HER2- Advanced Breast Cancer

February 2nd 2022

Laura Spring, MD, discusses next steps of the phase 1/2 AMEERA-1 trial in estrogen receptor–positive, HER2-negative advanced breast cancer.

Dr. Usmani on Emerging Treatment Strategies in Late Relapsed Multiple Myeloma

February 2nd 2022

Saad Z. Usmani, MD, MBA, FACP, discusses emerging treatment strategies in late relapsed multiple myeloma.

Dr. Tap on Developing Treatment Opportunities in Soft Tissue Sarcomas

February 2nd 2022

William D. Tap, MD, discusses developing treatment opportunities in soft tissue sarcomas.

Dr. Melenhorst on the Persistence of CD4+ CAR T-Cells in Inducing Remissions in CLL

February 2nd 2022

Jan Joseph Melenhorst, BSc, MS, PhD, discusses the persistence of CD4+ CAR T-cells in inducing remissions in patients with chronic lymphocytic leukemia.

Dr. Richardson on the Rationale for the UPNEXT Trial in Ovarian Cancer

February 2nd 2022

Debra L. Richardson, MD, FACS, FACOG, discusses the rationale for the ongoing phase 3 UPNEXT trial in platinum-sensitive ovarian cancer.

Women in Oncology: Lessons to Tell Up-and-Coming Female Oncologists

February 2nd 2022

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, provide advice to female oncologists who are just starting out their careers.

Women in Oncology: The Power of Mentorship in Overcoming Gender-Related Challenges

February 2nd 2022

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, discuss how and/or if any mentors they had during their careers helped them overcome gender-related challenges they experienced.

Women in Oncology: How Has the Culture of Oncology Practice Changed Regarding Gender Disparities?

February 2nd 2022

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, share insight on how the corporate culture has changed in oncology practices with regard to gender inequality.

Women in Oncology: CTCA Leads Share Gender-Related Obstacles in Oncology Careers

February 2nd 2022

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, discuss some of the gender-related obstacles that they experienced throughout their careers as female oncologists.

Dr. Klempner on the Results of the DisTinGuish Trial in Advanced Gastroesophageal Adenocarcinoma

February 1st 2022

Sam Klempner, MD, discusses the results of the ongoing phase 2a DisTinGuish trial in advanced gastroesophageal adenocarcinoma.

Dr. Shah on the Potential Clinical Implications of the GLOW Trial in Claudin 18.2+/HER2- Gastric/GEJ Cancer

February 1st 2022

Manish A. Shah, MD, discusses the potential clinical implications of the ongoing phase 3 GLOW trial in Claudin 18.2-positive, HER2-negative gastric/gastroesophageal junction adenocarcinoma.